Charles River Laboratories International (NYSE:CRL) EVP Sells $599,710.68 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 2,039 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $294.12, for a total transaction of $599,710.68. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,413,834.84. This trade represents a 29.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.0%

NYSE:CRL traded up $2.97 on Thursday, hitting $292.97. 1,059,340 shares of the company’s stock were exchanged, compared to its average volume of 927,192. The firm has a 50-day moving average price of $230.73 and a 200-day moving average price of $192.57. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $299.32. The company has a market cap of $13.99 billion, a P/E ratio of -60.41, a price-to-earnings-growth ratio of 2.89 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on CRL shares. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Mizuho set a $264.00 target price on shares of Charles River Laboratories International in a research note on Monday, August 10th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a report on Monday, July 20th. Barclays reaffirmed an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada lifted their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $255.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at $42,000. Sfam LLC bought a new position in Charles River Laboratories International during the fourth quarter worth $43,000. Activest Wealth Management boosted its position in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Elyxium Wealth LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at $46,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.